MARC보기
LDR00000nmm u2200205 4500
001000000329785
00520241016151504
008181129s2018 ||| | | | eng d
020 ▼a 9780438065741
035 ▼a (MiAaPQ)AAI10823072
035 ▼a (MiAaPQ)unc:17912
040 ▼a MiAaPQ ▼c MiAaPQ ▼d 248032
0491 ▼f DP
0820 ▼a 615
1001 ▼a Okumu, Denis O.
24510 ▼a LYN Regulates Drug Resistance Mechanisms in Chronic Myelogenous Leukemia (CML).
260 ▼a [S.l.] : ▼b The University of North Carolina at Chapel Hill., ▼c 2018
260 1 ▼a Ann Arbor : ▼b ProQuest Dissertations & Theses, ▼c 2018
300 ▼a 135 p.
500 ▼a Source: Dissertation Abstracts International, Volume: 79-10(E), Section: B.
500 ▼a Advisers: Lee M. Graves
5021 ▼a Thesis (Ph.D.)--The University of North Carolina at Chapel Hill, 2018.
520 ▼a Acquired resistance to anti-cancer therapy presents a critical challenge to effective clinical management of chronic myelogenous leukemia (CML). Drug-resistant CML cells devise diverse molecular adaptations to evade therapy. Examples of such ada
520 ▼a In the first project, I showed that increased Lyn expression and activity in Myl-R cells up-regulated the expression and stability of BIRC6, a member of the inhibitor of apoptosis proteins (IAP) family known to bind and inactivate active caspase
520 ▼a In the second project, I am investigating Lyn's role in regulating creatine uptake by Myl-R cells. Our lab previously showed that total intracellular creatine pool was 5-fold higher in Myl-R than Myl cells. Our unpublished data show that the inc
520 ▼a Taken together, these studies enrich our understanding of the diverse therapy-survival mechanisms utilized by CML cells, and provide insights into novel targets for effective cure of CML.
590 ▼a School code: 0153.
650 4 ▼a Pharmacology.
690 ▼a 0419
71020 ▼a The University of North Carolina at Chapel Hill. ▼b Pharmacology.
7730 ▼t Dissertation Abstracts International ▼g 79-10B(E).
773 ▼t Dissertation Abstract International
790 ▼a 0153
791 ▼a Ph.D.
792 ▼a 2018
793 ▼a English
85640 ▼u http://www.riss.kr/pdu/ddodLink.do?id=T14998539 ▼n KERIS
980 ▼a 201812 ▼f 2019
990 ▼a 관리자 ▼b 관리자